Gesellschaft für Biotechnologische Forschung mbH

As a centre for infectious diseases, the main focus of the GBF research activities is to study microbial virulence factors, host-pathogens interactions, and immunity to develop strategies for the diagnosis, prevention and therapy of human infectious diseases. More than seventeen million people die each year from infectious diseases, a third of all deaths worldwide. Newly emerging infections have devastating effects and reach many countries through global travel or exchange of blood products. Environmental changes or alterations in food processing allow new infectious agents to emerge, like the ''mad cow'' epidemic. Re-emerging infectious diseases that were once regarded as defeated are rising as a result of antibiotic resistance. For example in tuberculosis and malaria, multidrug resistance is developing against virtually all currently available drugs. Furthermore, opportunistic infections are a recurrent problem in immunocompromised patients and an aging population. Building on a broad expertise in chemistry, structural biology, bioinformatics, genetics, cell biology, cellular microbiology, immunology, and bacterial ecology, the GBF will concentrate its research activities to unravel basic mechanisms of infections. These studies will form the basis for the development of new strategies to fight human diseases and, in close collaboration with medical institutes, be translated into clinical research. As an additional important element in our strategic concept, the GBF-BTF (Biotech Facilities) will serve as a national and international platform which makes process development and biotechnology production accessible for industry and public research. The platform will provide high quality GMP biological products for clinical trials and non-GMP products for research.


Gesellschaft für Biotechnologische Forschung mbH

Mascheroder Weg 1
38124 Braunschweig
Forschung & Entwicklung
Forschung & Lehre
mehr als 500